3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
69
Fallopian Tube Neoplasms
18
Endometrial Neoplasms
8
Carcinoma, Ovarian Epithelial
8
Breast Neoplasms
7
Neoplasms
5
Pancreatic Neoplasms
3
Cystadenocarcinoma, Serous
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Prostatic Neoplasms
2
Ovarian Diseases
2
Neoplasm Metastasis
2
Gonadal Disorders
2
Genital Neoplasms, Female
2
Genital Diseases, Female
2
Endocrine System Diseases
2
Endocrine Gland Neoplasms
2
Carcinoma
2
Adnexal Diseases
2
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocytopenia
1
Sarcoma
1
Recurrent/ Advanced Stage Endometrial Cancer Patients
1
Recurrence
1
Prostatic Diseases
1
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
1
Platinum-resistant Ovarian Cancer
1
Interventions
pembrolizumab
24
Paclitaxel
7
Docetaxel
7
Cyclophosphamide
7
Carboplatin
7
fludarabine
6
Taxes
6
Nivolumab
6
Trastuzumab
5
Magnetic Resonance Spectroscopy
5
atezolizumab
4
Specimen Handling
4
Psychiatric Rehabilitation
4
Polymerase Chain Reaction
4
Gemcitabine
4
Fluorouracil
4
Cisplatin
4
tisotumab vedotin
3
fludarabine phosphate
3
Radiation
3
Oxaliplatin
3
Leucovorin
3
Irinotecan
3
Ipilimumab
3
Gene Expression Profiling
3
Drug Therapy
3
Counseling
3
Albumin-Bound Paclitaxel
3
zimberelimab
2
ulixertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
niraparib
×
Gynecologic
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts